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In order to evaluate strategies to reduce HIV transmission through breast milk and optimize both
maternal and infant health among HIV-infected women and their infants, we designed and
implemented a large, randomized clinical trial in Lilongwe, Malawi. The development of protocols
for large, randomized clinical trials is a complicated and lengthy process often requiring alterations
to the original research design. Many factors lead to delays and changes, including study site-specific
priorities, new scientific information becoming available, the involvement of national and
international human subject committees and monitoring boards, and alterations in medical practice
and guidance at local, national, and international levels. When planning and implementing a clinical
study in a resource-limited setting, additional factors must be taken into account, including local
customs and program needs, language and socio-cultural barriers, high background rates of
malnutrition and endemic diseases, extreme poverty, lack of personnel, and limited infrastructure.
Investigators must be prepared to modify the protocol as necessary in order to ensure participant
safety and successful implementation of study procedures. This paper describes the process of
designing, implementing, and subsequently modifying the Breastfeeding, Antiretrovirals, and
Nutrition, (BAN) study, a large, ongoing, randomized breastfeeding intervention trial of HIV-
infected women and their infants conducted at a single site in Lilongwe, Malawi. We highlight some
of the successes, challenges, and lessons learned at different stages during the conduct of the trial.
Keywords
Mother-to-child transmission of HIV; breastfeeding; HIV/AIDS; nutrition; study design and
management; antiretroviral drugs
Background
Among the estimated 700,000 children infected with HIV in 2003 worldwide, 315,000 were
infected through breast-feeding (1). Although some studies suggest that the risk of HIV
transmission is higher in the first months of life, others indicate a relatively constant risk of
transmission throughout breastfeeding beyond the first month (2–5). Various factors have been
associated with increased HIV transmission through breast milk including mastitis, cracked
nipples, elevated maternal plasma and breast milk (BM) viral load, low maternal CD4 count
and advanced stage of HIV disease, and mixed feeding (giving infants solid foods or other
liquids in addition to breastmilk) (5–15).
Despite the risks of HIV transmission, the many advantages of breastfeeding have been well
documented. The practice is known to confer nutritional, immunologic, developmental,
psychologic, social, and economic benefits including overall lower infant morbidity and
mortality. Compared with formula-fed infants, breastfed infants have fewer gastrointestinal
and lower respiratory tract infections and are less likely to develop otitis media, necrotizing
enterocolitis and other diseases, particularly in the first six months of life (16–24). The greatest
benefits accrue to exclusively breastfed infants (infants who only receive breast milk), who are
less likely to have diarrheal or respiratory illness, to develop atopic disease, and to become
infected with HIV than infants who receive both breast milk and other liquids or solids(15;
18;25–27).
Breastfeeding also provides benefits to the mother including a delay in resumption of ovulation,
resulting in increased child spacing (16). In addition to individual health benefits, there are
economic and social benefits due to savings from formula purchases (16;28). Producing breast
milk of adequate quantity and quality is, however, nutritionally demanding for mothers,
particularly for those who have chronic infections. Unless diet during pregnancy and lactation
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is adequate, prolonged breastfeeding is likely to lead to maternal nutritional depletion
(inadequate nutritional intake compared to metabolic needs) (29–32). Depletion leading to
rapid weight loss may place HIV-infected mothers at greater risk of succumbing to
opportunistic infections, indirectly increasing their disease progression and risk of death (32;
33).
Thus, HIV-infected women in resource-limited settings are faced with a tragic dilemma –
breastfeeding their infants with its associated risk of HIV transmission or protecting their
children from HIV by replacement feeding (anything other than breast milk), which may also
be nutritionally less demanding for themselves, but increases the infant’s risk of malnutrition
and death if replacement feeding is not affordable, feasible, and safe (34;35).
Current WHO recommendations emphasize that (1) breastfeeding should be supported and
promoted in the general population, irrespective of HIV infection rates; (2) there should be
improved access to HIV counseling and testing; and, (3) HIV-infected women should be fully
counseled about the benefits of breastfeeding, the risk of HIV transmission through
breastfeeding, and the risks and possible advantages associated with other methods of infant
feeding. Exclusive breastfeeding for the first 6 months is recommended in the general
population and for HIV positive mothers who breastfeed. Recently revised recommendations
state that early breastfeeding cessation should only be considered if criteria for replacement
feeding are met (36).
In Malawi, liquid formula is impractical due to the weight and shipping costs. The cost of dry
formula is $13.60 month for an infant age 7–12 months, which far exceeds the per capita health
budget in most sub-Saharan countries (28). Powdered formula must be mixed with water, which
is often contaminated and can lead to severe and sometimes fatal diarrheal disease (17;18;
34). In addition Malawi guidelines follow the WHO guidelines.
In light of the complex risk-benefit ratio of breastfeeding for HIV-infected mothers and their
infants, there is an urgent need to identify ways to make breastfeeding safer for both mothers
and infants in resource-limited settings. In Lilongwe, Malawi, despite broad coverage of
prevention of mother-to-child transmission (PMTCT) programs that offer short-course
perinatal antiretroviral regimens to HIV-infected women (37), the risks of HIV transmission
during the postnatal period are still substantial due to nearly 100% breastfeeding, almost no
weaning before 12 months, and negligible exclusive breastfeeding, thus minimizing the effect
of the PMTCT program.
In April 2001 the Centers for Disease Control and Prevention and the University of North
Carolina began designing the Breastfeeding, Antiretrovirals and Nutrition Study, hereafter
referred to as BAN, a randomized clinical trial to address these issues. The purpose of the study
was to evaluate the following: 1) the benefit and safety of antiretroviral prophylaxis given
either to infants or to their mothers to prevent HIV transmission during breastfeeding, 2) the
benefit of nutritional supplementation given to the women during breastfeeding to prevent
maternal depletion, and 3) the feasibility of exclusive breastfeeding followed by early, rapid
breastfeeding cessation. To evaluate the first two objectives, two interventions were assessed
in a factorial design: 1) a 3-arm postnatal antiretroviral intervention with additional drugs given
to the mother or infant, or nothing in addition to an enhanced standard perinatal prophylaxis,
and 2) a 2-arm maternal nutritional intervention to promote maternal health with a food
supplement given to half the mothers. The third objective, assessing feasibility of exclusive
breastfeeding, is assessed in an observational fashion and does not involve a comparison group.
This paper describes the process of designing and implementing this protocol in the field, as
well the evolution of this protocol to reflect changes that were implemented to meet the
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changing local and international realities over a seven year period. We highlight some of the
successes, challenges, and lessons learned at different stages during the conduct of the trial.
Methods
Location and Personnel
Malawi is a country slightly smaller than Pennsylvania in size with a population of 13,571,000,
bordered by Zambia, Mozambique and Tanzania in southern Africa. The adult literacy is 64%
and the gross national income (GNI) is $170 placing Malawi at 203 out of 209 countries in
terms of poverty. Per capita annual health expenditure is 58 dollars. Lilongwe is the capital
with a population of 744,000. Most of the population speaks Chichewa although most
professionals speak English as well. Faculty from the University of North Carolina has been
working in Malawi since 1990. In-country activities in Lilongwe are coordinated and overseen
through the UNC Project, a program providing clinical care, training, technical advice and
research and which is headed by a resident country director and staffed with more than 300
medical and laboratory personnel from Chapel Hill and Malawi including physicians, clinical
officers, nurses and nutritionists All of our Malawi and US team members receive training and
certification in human subjects protections as well as either Good Clinical or Good Laboratory
Practice. Key Malawi team members were brought to the US for additional and more specific
laboratory training (cell separation, PCR, microbiology assays) as well as the data management
systems we used (Laboratory Data Management System by Frontier Science Foundation and
TELEform™ software by Cardiff). We provide health benefits and transportation for staff.
Recruitment and Screening
The University of North Carolina at Chapel Hill currently administers a prevention of mother-
to-child transmission (PMTCT) program at four government clinics in Lilongwe, the capital
of Malawi, and also provides technical assistance for nine other PMTCT sites run by the Malawi
Ministry of Health (36;37). The PMTCT program offers HIV counseling and testing to all
pregnant women as well as enhanced antenatal care and single-dose nevirapine prophylaxis
given to all HIV-infected women in labor and to their infants shortly after delivery (i.e. the
HIVNET 012 regimen). HIV testing is conducted using two simultaneous rapid tests, Abbott
Determine HIV-1/2 and Uni-Gold HIV (Trinity Biotech plc, Bray, Eire). The Bioline HIV-1/2
3.0 (Standard Diagnostics, Kyonggi-do, South Korea) is used as a tie-breaker in the event of
conflicting results. Among the more than 28,000 pregnant women tested each year, the HIV
seroprevalence rate is about 13%. Through this program all HIV positive women receive
cotrimoxazole if their CD4 count is less than 500 cells/μL and all HIV-exposed infants receive
the same once they reach 6 weeks of age. Antenatally, all women receive iron and folate,
screening for syphilis and anemia, malaria prophylaxis, mosquito nets and tetanus toxoid.
Postnatally, all infants receive routine vaccinations which include BCG, polio, diphtheria,
pertussis, tetanus, Haemophilus influenza, hepatitis B, and measles. All women with low CD4
counts (<200–250 cells/μL), identified either through the PMTCT program or subsequently
through the BAN screening process, are referred to the Lighthouse Clinic, a Ministry of Health
sponsored facility which provides antiretroviral therapy through the Global Fund.
Women identified as HIV-infected are offered referral to the BAN study clinic at Bwaila
Hospital. Women who are willing to participate and intend to breastfeed are asked to sign a
screening consent. For women who consent to be screened, specimens are collected and a
medical history obtained to assess eligibility. Primary eligibility criteria include: 1) ≤30 weeks
gestation, 2) at least 18 years of age (or 14 years of age if married), 3) hemoglobin >7 g/dL,
4) CD4 count ≥ 250 cells/μL, 5) no prior antiretroviral medication use, 6) normal liver function
tests (<2.5 upper limit of normal), 7) no serious complications of pregnancy, and 8) not
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previously enrolled in the BAN study. Women meeting these eligibility criteria are asked to
return for 4 additional antenatal study visits.
All women enrolled in BAN are asked to deliver at Bwaila Hospital. However, women who
deliver elsewhere are eligible as long as the mother and infant arrive at Bwaila Hospital for
evaluation within 36 hours of birth. In order to be eligible for randomization, additional criteria
must be met: 1) infant birth weight ≥2000 grams, 2) no severe congenital malformations or
other conditions incompatible with life, and 3) based on clinical assessment, no maternal
condition which would preclude start of study drug. Eligible mother-infant pairs are
randomized to one of six treatment arms (see section on Factorial Design, and Table 1). Infants
found to be perinatally HIV-infected at birth or at two weeks of life, and their mothers, are
subsequently disenrolled from the study and referred for recommended antiretroviral treatment.
We collected maternal breastmilk, peripheral blood mononuclear cells (PBMCs), plasma,
serum and cell pellets as well as infant PBMCs, plasma, serum, dried blood spots and cell
pellets. The specimens were collected for viral loads and genotypes, drug levels, measurement
of other viruses, vitamin levels, immunological studies and possible genetic typing.
Antiretroviral, nutritional, and other interventions for all participants
All mother-infant pairs enrolled in the study receive certain antiretroviral medications and
nutritional and other benefits, regardless of the arm to which they are assigned. In addition,
mother-infant pairs receive medical care from the study staff that exceeds the standard of care
for Malawi. For equity purposes and due to seasonal food shortages, all participants received
2 kg of maize each week. Although the nutritive quality of the maize varies over time, this
ration provides approximately 200 kcal per person per day for a family of five. Any infant or
mother presenting with an intercurrent illness has full medical care provided by UNC Project.
To achieve this level of care, we built microbiology and other clinical laboratories for diagnosis
and treatment of pneumonia, sepsis, meningitis, infectious diarrhea, tuberculosis, and malaria.
All enrolled mothers receive single dose nevirapine (the HIVNET 012 regimen) peripartum
plus twice a day zidovudine (ZDV) 300 mg and lamivudine (3TC) 150 mg during labor and
for 7 days postpartum. When infants receive their single dose nevirapine (NVP) 2mg/kg after
delivery they also begin ZDV (12 mg) plus 3TC (6 mg) twice daily for 7 days. Women receive
a single vitamin A supplement post partum and counseling on exclusive breastfeeding (EBF)
and on rapid, early breastfeeding cessation between 24 and 28 weeks postpartum. Study
subjects receive the equivalent in Malawi currency of US $4 per study visit or interim visits
for illness and US $10 for delivering at the health center (see section below for study visit
schedule).
Factorial Study Design
After delivery, participants are randomized according to 1 of the 6 treatment conditions using
a permuted block method (Table 1). That is, assignments are randomly allocated in groups of
6 or more, in order to ensure a balanced allocation. The group size varies randomly between
6, 12, and 18, in order to prevent discovery of the allocation scheme by study researchers. The
study’s target sample size is 2418 mother-infant pairs, with 403 assigned to each treatment
combination. There are 17 scheduled study visits: 2 antepartum screening visits, an enrollment
visit soon after delivery, and postpartum visits at 1, 2, 4, 6, 8, 12, 18, 21, 24, 28, 32, 36, 42,
and 48 weeks postpartum. The enrollment visit, during which women are randomized, is
generally conducted during the delivery hospitalization unless the woman delivers at another
hospital. In addition to the regularly scheduled visits, women who register for the study early
may have additional study visits antenatally at 28, 32, and 36 weeks estimated gestational age,
as well as postnatally, whenever they feel the need for additional medical care. Data are
systematically collected for all unscheduled interim visits.
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In this factorial design, half of the study mothers are randomized to receive a high-energy,
high-protein, micronutrient-fortified food supplement (Table 2). The supplement provides the
daily energy required to support exclusive breastfeeding and 100% of the recommended dietary
allowance for all micronutrients except vitamin A, which has been associated with increased
postnatal HIV transmission when consumed daily (38). The supplement is supplied for 28
weeks after delivery, or until reported breastfeeding cessation, whichever occurs first.
All women who experience excessive weight loss, defined as 5% or more of body weight,
between visits beginning 4 weeks after delivery or a body mass index (BMI=kg/m2) that falls
below 17, are examined by a clinician and provided with nutritional supplement if they were
not already receiving it through week 28.
For mothers or infants randomized to the antiretroviral (ARV) arms, study drugs are supplied
for 28 weeks after delivery or until reported breastfeeding cessation, if earlier. Infants assigned
to the ARV arms receive daily NVP, with doses ranging from 6 mg to 26 mg, increasing as
the infant ages up to 28 weeks (39) We utilized a simplified dosing regimen that is easy to
administer (Table 3) in a resource-limited setting, as it does not rely on infant weighing.
Mothers assigned to the maternal HAART regimen received combination therapy with three
drugs. At the beginning of the study, postpartum mothers assigned to HAART received 300
mg ZDV, 150 mg 3TC taken orally every 12 hours for 28 weeks as well as NVP 200 mg once
daily for 14 days and then 200 mg every 12 hours. Mothers who develop toxicity to the ZDV
component were switched to stavudine and those that are intolerant of NVP were switched to
nelfinavir.
The median duration of breastfeeding in Sub-Saharan Africa is 18 months (40). To minimize
the risks of malnutrition following early breastfeeding cessation, the study provides mothers
with a locally produced ready- to-use therapeutic food (RUTF) commonly used in Malawi for
treatment of severe acute malnutrition in children. The RUTF is made from full-cream
powdered milk, peanut butter, sugar, oil, and fortified with micronutrients. No water is needed
for mixing, making it safer than other products that require reconstitution with potentially
contaminated water supplies. Infants can suck the peanut butter spread from a spoon. The breast
milk replacement food ration provides approximately 400 kcal and 9.5 g of protein per day for
the study children from 28 to 48 weeks of age. Although this RUTF has been used extensively
in several countries, (including Malawi, Ethiopia, Chad and Niger) for home treatment of
severe acute malnutrition, this study uses it as a breast milk replacement food (41–45). Mothers
were also counseled to provide local, complementary weaning foods.
Statistical Analysis
BAN has three primary study outcomes: 1) HIV transmission to infants, 2) maternal depletion,
and 3) feasibility of exclusive breastfeeding followed by rapid weaning.
1. Prevention of HIV transmission to infants. Assessment of antiretroviral treatment
efficacy is based on differences in the proportion of infants free of HIV infection at
28 weeks. The target sample size of 2418 mother-infant pairs was calculated assuming
7% cumulative HIV infection rate in the control arm by 28 weeks of age in infants
who are uninfected at birth or 2 weeks postpartum. This estimate is based on studies
of transmission of HIV to the infant through breastfeeding, including a meta-analysis
of published evidence (46;47). We allowed for 8% of infants to be disenrolled due to
evidence of HIV by 2 weeks (48), an additional 10% of mother-infant pairs to be lost
to follow-up by 28 weeks, and 7 interim analyses based on O’Brien-Fleming
guidelines. The assumption for the cumulative infant HIV infection rate by 28 weeks
in the antiretroviral treatment arms was 3%. Using a 0.025 significance level to adjust
for multiple comparisons with the control arm, the sample size was chosen to provide
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at least 80% power to reject the null hypothesis of no difference in HIV incidence
between the control arm and a treatment arm. Two-sided log-rank tests will test the
two null hypotheses comparing (i) maternal HAART versus no maternal or infant
antiretrovirals and (ii) infant antiretrovirals versus no maternal or infant
antiretrovirals. Infant deaths prior to HIV diagnosis will be analyzed both as right
censored observations and as a component of the composite endpoint of death or HIV
infection, whichever occurs first. To guard against potential selection bias induced
by conditioning on the post-randomization event of HIV infection at 2 weeks we will
also conduct an intent-to-treat (ITT) analysis of HIV infection rates whereby all
infants will be included in the analysis, regardless of HIV status at birth or 2 weeks.
Infant HIV infection is determined by qualitative Roche HIV-1 Amplicor DNA 1.5
PCR at weeks 12 and 28 with requirement for a confirmatory test.
2. Prevention of maternal nutritional depletion. Evaluation of the effectiveness of the
nutritional supplement for preventing maternal depletion will be based on weight loss
between 4 and 28 weeks post-partum. For this outcome we anticipate that mothers
not receiving a supplement will lose 0.17 kg/month and mothers receiving a
supplement will lose 0 kg/month with a constant standard deviation 1.32 (32). The
study sample size as calculated above has over 90% power to detect a difference of
0.20 kg in mean maternal weight loss from 4 to 28 weeks.
3. Feasibility of exclusive breastfeeding for 24 weeks followed by rapid weaning. We
will examine the proportion of mothers reporting breastfeeding cessation and the
proportion of infants whose weight for age is below the World Health Organization
5th percentile before and after weaning and infant survival from reported breastfeeding
cessation or 28 weeks, whichever is earlier, through 48 weeks. We will also examine
growth faltering of infants, defined as a decline of weight for age z-score of more than
one standard deviation, as well as HIV transmissions to the infant that occur beyond
28 weeks. Evaluation of this objective will be based on the descriptive data mentioned
above rather than quantitative a priori assumptions.
Results
The initial study idea was created in response to an April 2001 Request for Proposals from the
US Centers for Disease Control and Prevention, submitted in June 2001 and funded in October
2001. As the protocol was being developed, we conducted a series of formative research
projects over a two-year period in Lilongwe. Using data generated from multiple focus groups,
client home visits, and individual in-depth interviews and taste tests of the nutritional
supplement among pregnant women, spouses, civic leaders, healthcare workers, HIV-infected
breastfeeding women and family members, the team gauged the feasibility of the proposed
protocol (49;50). This shaped many decisions in protocol design; for example, we learned that
mothers considered drawing blood from healthy babies at birth feasible and acceptable but had
concerns about the volume to be drawn, and we used this information when formulating the
biological sample schedule and volumes. We also learned that mothers preferred a longer
weaning period, rather than more rapid weaning, for their own and the babies’ comfort and
safety and to assure good infant transition to other foods. This shaped our decision to allow a
month-long weaning period at 6 months of infant age. Mothers expressed concern about the
impact of weaning on the nutritional status of their infants and so we provide locally produced
RUTF from weaning through 48 weeks post-partum. We also tested the acceptability among
mothers of the choice of the maternal nutrition supplement. We placed emphasis on mother’s
health during breastfeeding, and provided a family food supplement. Without the formative
research many of these issues may have gone unaddressed and could have undermined the
successful implementation of the BAN study. The result was an evidence-based protocol
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ensuring participant understanding of the research, safeguards for the participants, and
increased feasibility and acceptance of clinical research in this community.
While English is the official language of Malawi, Chichewa is the common local language
widely used throughout the country. Though many of our patients do not speak English, all
study staff spoke both English and Chichewa. The adult literacy rate in Malawi is
approximately 64% (51). Prior to initial enrollment, the language of our consent forms was
dramatically simplified compared to the standard language found in many standard consent
forms. Due to language and literacy issues, we felt that a long and complicated consent form
was not ethical. For example, we did not mention chemical names of compounds but rather
emphasized the potential toxicities they caused. All consents were translated into Chichewa
and then back translated by a separate team into English to ensure that they met international
standards. All study forms, which contained questions to be asked patients, were in Chichewa.
The study team used the WHO CIOMS Guidelines for Biomedical Research Involving Human
Subjects when the study was designed and held an ethics consultative meeting with an outside
ethicist prior to submitting the final protocol.
Once the final protocol was developed, it was submitted for review at three separate
institutional review boards in 2003: the parent institution, the sponsoring agency, and the host
country. Since each IRB had its own comments on the protocol, we reconciled all with final
approval by all three IRBs in March 2004, thirty months after the initial award. In parallel with
this process, negotiations for donations of study drugs were conducted.
BAN began enrolling participants in April 2004. Initially, enrollment was relatively slow. In
order to increase enrollment, we engaged in community outreach to dispel rumors about the
study, including discussions with tribal elders and leaders. We noticed that many women who
initially expressed interest in the study failed to return for their screening and enrollment visits.
Upon further questioning, it became clear that many husbands were not supportive of the study.
To address this, we developed community activities specifically targeting men, such as weekly
support groups for men. In addition to community activities, two recruitment sites were added
in other areas of Lilongwe. Although the main study activities, including all clinical visits,
remained at one site, these two additional sites provided a larger pool of potential study
participants. By February 2006, enrollment had increased to our target of 15 enrollees per week.
It has remained relatively stable since.
Prior to initiating the study we realized that unlike shorter term studies, we would be following
these women and their infants for more than 12 months. Usually, such care is provided by the
understaffed public sector, which also suffers from frequent stock outs of critical medicines
and often lack diagnostic facilities. Since we felt an ethical obligation to provide clinical care
for intercurrrent illnesses, we purchased all the medications for intercurrent illnesses, hired
additional staff to provide for non-study related care and built a microbiology laboratory.
Although we have not completed a formal cost analysis such clinical care consumes an
additional 25% of the study costs.
To date, there have been twelve subsequent amendments made to the protocol and submitted
to the three regulatory agencies (Table 4). Modifications were made to increase toxicity
monitoring in light of new data on nevirapine hepatotoxicity (52), ours and others’ discovery
of benign ethnic infant neutropenia (53;54) which is a temporary, clinically insignificant
laboratory finding, better understanding of nevirapine resistance (55), FDA advisories (56),
changing national and international guidelines for treatment of adults and need for
cotrimoxazole prophylaxis (57;58), a change in the NIH Toxicity Tables, and several changes
to decrease the protocol burden on the clients and the staff. We also decided that longer follow
up may be necessary and thus altered the consent form to allow for contact after the study
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ended. These amendments can be grouped as those implemented to address toxicities, those to
decrease the enormous workload of the study, and those to meet the changing reality of HIV
care. After the initial IRB application, which took many months of negotiating between the
three IRBs, the process has decreased to 2 months or less for each amendment. Although, each
of the IRBs would sometimes ask for clarification or ask us to amend the consent form, there
were no excessive delays or unwanted requests. On two occasions, for safety and ethical reasons
the IRB’s were notified simultaneously of the problem and our action plan. This applied to our
handling of the nevirapine toxicity issue and after the DSMB recommendation to stop one arm.
Amendments for new information regarding toxicities
Within weeks of assigning women to HAART containing NVP, we became aware of a need
to increase the monitoring for hepatic toxicity. In February 2004, Boehringer-Ingelheim had
sent a “Dear Doctor” letter outlining changes to the Black Box Warning for nevirapine, which
stated that women with CD4 counts greater than 250 cells/μL had a 12-fold higher risk of
hepatotoxicity, usually within six weeks of initiating therapy. On January 19, 2005 the FDA
strengthened the warning to recommend against starting nevirapine treatment in women with
CD4 counts greater than 250 cells/μL unless benefits clearly outweigh risk (56). Among the
first 39 women randomized who received nevirapine-containing HAART, we found 3 severe
rashes, 1 case of clinical hepatitis and 5 cases of severe elevations in hepatic transaminases.
We subsequently have shown that nevirapine drug levels are higher in Africans compared to
Americans (59). Even though we did not have any fatal complications, conducting a study in
a resource-limited country requires a higher standard beyond safety and efficacy; that of
feasibility of eventual national roll out of the regimen. The requirement for close monitoring
of transaminases necessitating a large number of clinical and laboratory staff clearly made this
an infeasible regimen for eventual implementation in breastfeeding women with high CD4
counts in Malawi. We initially switched all breastfeeding mothers assigned to HAART from
nevirapine to our second-line regimen containing nelfinavir and ultimately, for reasons of
availability, safety and potency, to lopinavir/ritonavir (Kaletra).
The NIH toxicity tables were developed by the NIH Division of AIDS (DAIDS) in the
beginning of the AIDS epidemic in the United States. Although widely used in clinical trials,
we found early in the conduct of BAN that they do not take into account the benign neonatal
neutropenia seen in both African-Americans and black Africans (53;54). In our first months
we noticed that of 206 newborns enrolled, 22 had grade 3 or 4 neutropenia (9 present at birth)
without any clinical sequelae and with spontaneous recovery of the absolute neutrophil counts
within weeks. We, therefore, modified the infant neutropenia criteria for our protocol to define
grade three toxicity for any age infant to include an ANC less than 400 cells/μL, which
decreased the incidence of grade 3/4 neutropenia to less than 1%. Subsequently, DAIDS did
modify their toxicity table, although not to the extent of our revision (Table 5).
In 2006 the NIH Division of AIDS modified infant anemia criteria to state that any hemoglobin
less than 9.0 g/dl for HIV negative infants at least 57 days old was at least a grade 3 toxicity.
The previous version cited a hemoglobin value of less than 7 g/dl as the cut-point for grade 3
anemia. This new table was adopted by BAN in May 2006 and led to an artificial increase in
grade 3/4 anemia from 55 newborn infants to 238 in the first 1233 mother infant pairs
randomized.
Amendments to decrease workload
With a weekly accrual target of 15 mother-infant pairs, the overall workload of BAN is
considerable. Due to the complex design and multiple objectives, lengthy questionnaires, and
the need for close participant monitoring, study visits were taking up to 8 hours to complete,
sometimes requiring drivers to take clients home in the evening, in some cases requiring return
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visits, and placing an undue burden on participants. In addition, the sheer volume of data
generated, including over 20,000 pages scanned per month, jeopardized the quality of the data
obtained. With the onset of the rainy season each November in Lilongwe, sick (i.e.
unscheduled) visits to the study clinic increased precipitously, placing a huge burden on project
staff and increasing study costs dramatically. From July 2005 until June 2006, there were 1800
scheduled study visits and 400 unscheduled visits for the first 883 mother infant pairs
randomized, usually due to intercurrent illnesses. These additional visits increased annual costs
by $362,000 (29%) in additional personnel and laboratory costs.
With this burden on clients, staff and study budget, we quickly realized that several elements
of the original protocol were not feasible. Since many of our patients are not literate, our staff
would read the consent to them, pausing for questions and clarifications. In addition, the study
staff uses a consenting checklist to ensure that important areas have been covered and are
understood by the client. The study consent process was taking up to 2 hours to complete. Since
28% of consented women were subsequently determined to be ineligible, (half because they
did not meet primary eligibility due to CD4 count or hemoglobin level and half because they
delivered at home and did not present in time to the study clinic or had other complications),
we decided to split the consent process into a screening registration form and a post-partum
randomization form. This both shortened the original consent and the time imposed on the
patients as well as sparing those, who would not be eligible, from having to sit through the
description of the study after delivery. In addition, the PMTCT program, which refers potential
participants to BAN, began routine CD4 testing thereby allowing women with low CD4 counts
to be excluded from the study and referred to appropriate care without referral to BAN.
The burden on study participants was also great due to the number and length of visits. In order
to complete the study, mothers came to clinic for at least 17 visits and infants for at least 15
visits with blood drawn at every visit. When 900 women-infant pairs had been randomized,
we systematically reduced the data collected to focus on key study endpoints. Case report forms
across the study had questions reduced. Reductions were made in demographic, delivery
history, breastfeeding, infant feeding, infant and maternal anthropometry, ARV adherence, lab
and physical exam forms. Twenty of the over 70 forms in the study were modified. After we
had randomized 1600 mother infant pairs, we further reduced the case report forms. This
reduction was mainly through the elimination of forms or number of times a form, such as the
infant and maternal 24-hour dietary recall, is administered. Deleted forms included the breast
health history, detailed breast exam, and detailed information about breastfeeding and early
weaning practices. At the peak, we estimate that collectively, staff was spending 1941 hours
per month filling out forms, which was reduced to an average of 1608 hours after the first
reduction in 2006 and to 1135 hours after the second reduction in 2007, resulting in an overall
reduction in workload of approximately 40%. Although we had pilot tested many of the forms,
in retrospect we realized that in advance of the study it would have been helpful to devote more
time to practice runs of the visit procedures including completion of the forms.
We originally planned to use case report forms with diagnostic algorithms for each
opportunistic and endemic infection similar to those used in US HIV clinical trials. Even with
modifications reflecting locally available tests, it was clear that these forms were infeasible.
For instance, almost no one obtained a chest radiograph for initial diagnosis of pneumonia. We
stopped using those forms and substituted an adverse events log to make it easier for staff to
track onset and completion of various events including adverse events, endemic and
opportunistic infections and concomitant medications.
In addition to reducing data collection, we also cut back on specimen collection. Thirty-nine
months into the study we stopped freezing cell pellets, peripheral blood mononuclear cells,
and pharmacokinetic samples in order to cut costs. Previously, we were freezing on average
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5,680 breast milk vials, 3,100 plasma vials, 500 cell pellet vials and 1,400 peripheral blood
mononuclear cell vials monthly. After implementing our amendments this decreased to 1,350
plasma vials monthly. None of the primary endpoints required any of the discontinued
questions or specimens.
Amendments to meet the changing realities of HIV care
In a study initiated during 2004 in a rapidly changing field, it was unavoidable that new data
would appear that might require changes to the protocol. In an effort to minimize development
of nevirapine resistance in women randomized to a HAART regimen containing nevirapine,
we added a 7-day Combivir tail after the nevirapine was stopped. This was an approximate
adjustment for the prolonged serum half-life of nevirapine compared to the relatively short
half-life of Combivir.
The Malawi Ministry of Health guidelines for HAART treatment changed the CD4 threshold
below which antiretroviral therapy was to be started from a CD4 count of <200 cell/ μL to <
250 cell/μL. In response, we changed the BAN enrollment criteria to exclude women who had
CDC counts of <250 cell/ μL; these women were referred for antiretroviral therapy. The Malawi
Ministry of Health also instituted routine cotrimoxazole prophylaxis for HIV-infected adults
and HIV-exposed infants. As of December 2005, all women in BAN with CD4 counts <500
cell/μL were started on cotrimoxazole after the first trimester. In addition, all children aged 6
weeks or above received cotrimoxazole until 3 months after discontinuation of breastfeeding.
For HIV-infected infants the prophylaxis is continued indefinitely.
Discussion
With a target sample size of 4836 total participants, which includes 2418 mothers and 2418
infants, BAN is among the largest single-site HIV trials in Africa (27;34;47;60–66). To conduct
a study of this magnitude, it is critical that the study leadership stay focused on the primary
objectives and that components, which place an undue burden on the study staff and the
participants are quickly identified and minimized. In addition, large and complex studies like
BAN must be flexible enough to rapidly respond to evolving changes in both science and
national and international policy, as well as the demands of multiple institutional ethics and
monitoring boards. When enrollment takes a long time to complete, results from on-going
related studies may affect clinical equipoise between study arms and necessitate alterations to
the protocol (67;68). If changes cannot be rapidly implemented, then enrollment may have to
be temporarily or permanently suspended, which can disrupt study flow and undermine staff
and participant trust and consequently future enrollment. When the information about liver
toxicity of nevirapine in women with high CD4 counts emerged, BAN was able to promptly
switch the women from nevirapine to the second-line protease inhibitor and inform the IRBs
without having to halt enrollment. In addition, preliminary findings from BAN helped shape
the conduct of other related studies. For example, the benign ethnic infant neutropenia in
African infants that we noted early on in BAN helped support the modifications of the DAIDS
toxicity table.
There are several potential disadvantages to protocol modifications once a study has begun.
These include inducing confusion in study staff, participants and the wider community. We
minimized this by conducting regular staff training around each major protocol change
combined with extensive community outreach by a dedicated group of community nurses.
Discontinuation of samples and forms collected must always be viewed through the lens of its
impact on the major primary and secondary endpoints and to ensure that data quality and the
ultimate outcomes do not suffer. Protocol changes occur over time and conditions can change
over time as well, which can induce unanticipated bias. These include local endemic diseases,
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which vary with the rainy season, such as malaria and diarrheal disease and the nutritional
status of the study participants.
By focusing on both maternal and infant outcomes, BAN is unique among mother-to-child
HIV transmission trials, which tend to focus primarily on HIV transmission to the infant. In
addition to the importance of promoting women’s health in its own right, there is evidence that
infants born to HIV-infected women, who subsequently die, are at markedly increased risk of
morbidity and mortality, even when they themselves are uninfected (69). Therefore, it is
imperative that trials balance the risks and benefits of infant feeding options for both the mother
and the infant. Another unique component of BAN is the inclusion of both an antiretroviral
intervention as well as a nutritional intervention. We chose a factorial design in order to
efficiently study two separate research questions evaluating the effectiveness of two
independent interventions within the same study population. Use of a factorial design reduced
costs, personnel and resources needed to answer two study questions, which is crucial in an
area of limited staff and resources, such as Malawi.
Another issue that many large trials face is attracting participants. We did experience initial
slow enrollment in BAN which we were able to successfully address by adding two recruitment
sites and by actively engaging the community, including local leaders and the women’s male
partners and dispelling rumors that inevitably arise and are related to the local societal and
political context. In this respect, the importance of including social scientists such as
anthropologists and health behavior experts from both Malawi and the US as part of the research
team and the need for formative research cannot be overemphasized; formative research at the
beginning of our trial helped inform the design of several study processes, including consenting
study participants, study visit flow, blood sampling, nutritional counseling and broader
community engagement. Including local investigators on the design team with an eye to
conform the protocol to local culture is essential. Although we did not conduct a pilot study,
we believe that had we done this, fewer amendments would have been necessary. Formative
research and pilot studies conducted before hand can gauge acceptance of the protocol design,
potential pitfalls and solutions to them.
One of the greatest challenges for BAN has been the provision of clinical care in a setting of
limited staff and resources. At 79 deaths/1,000 live births (70) and 1100 deaths/100,000 live
births (71) respectively, Malawi’s infant mortality rate and maternal mortality rate are among
the highest in the world. Women’s life expectancy is low at 45.7 years (72). Conducting a large
randomized trial in such a context of high disease burden and limited resources requires that
the study provide a high volume of clinical care and be prepared for a large number of
unscheduled visits for illness. If not appropriately factored in when planning the study, this
can severely drain study resources, as we learned firsthand throughout the conduct of this study.
This is an ethical imperative that funding agencies must address.
Recruiting and training skilled personnel can be difficult. For example, like many parts of the
world, there is a severe nursing shortage in Malawi, with many highly trained nurses emigrating
to other parts of the world (73). In order to not drain national resources, BAN has a written
policy of not hiring nurses currently working for the government. Within this context, hiring
and retaining nurses for BAN is challenging. However, the provision of training and other
professional opportunities for BAN staff has allowed us to attract and retain many qualified
staff members.
The research questions BAN addresses, how to minimize HIV transmission to infants
postnatally while ensuring optimal infant nutrition and maximizing maternal health, are
multifactorial and complex, thereby requiring a multi-component and complex study design.
Our hope is that what we learn from BAN will help shape national policy in Malawi and
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international guidance from WHO for how best to feed infants born to HIV-infected women
and how best to support lactating HIV-infected women in resource-limited settings where
formula feeding is not feasible, safe, and affordable.
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Table 1
Factorial design treatment arms
No ARV Infant ARV Maternal HAART
No nutritional supplement 403 No supplement No ARV 403 No supplement Infant Daily
NVP
403 No supplement Maternal HAART
Nutritional supplement 403 Supplement No ARV 403 Supplement Infant Daily NVP 403 Supplement Maternal HAART
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Table 2








B1 (thiamin) 1.6 mg
B2 (riboflavin) 1.8 mg
B3 (niacin) 20 mg equiv
B6 (pyridoxine) 2.2 mg
B12 (cyanocobalamine) 2.6 μg
C (ascorbic acid) 100 mg
E (α-tocopherol) 12 mg
Folic acid 300 μg
Iodine 200 μg
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Table 3
Infant dosing regimen of nevirapine
Age Dose Rounded-off dose
0–7 days 0.6 mL (6 mg) once daily 1 mL
7–14 days 0.6 mL (6 mg) once daily 1 mL
3–4 weeks 1.5 mL (15 mg) once daily 2 mL
5–6 weeks 1.8 mL (18 mg) once daily 2 mL
7–8 weeks 2.0 mL (20 mg) once daily 2 mL
9–12 weeks 2.2 mL (22 mg) once daily 2 mL
13–18 weeks 2.4 mL (24 mg) once daily 2 mL
19–20 weeks 2.6 mL (26 mg) once daily 3 mL
21–28 weeks 2.8 mL (28 mg) once daily 3 mL

















April 2003 Protocol submitted to three IRBs (UNC, CDC, and Malawi) for initial review.
Nov 2003 As three primary approvals (by UNC, CDC, Malawi) on different versions of protocol, amendment #1 submitted to all IRBs to reconcile minor
change
June 2004 Splitting consent process into screening and enrolment and increasing monitoring for hepatic toxicity
Sept 2004 Modifying dose of 3TC of infants switched from NVP. Modification of neutrophil cutpoints in infants
Dec 2004 Addition of 7 day tail of CBV at 28 wks for those assigned NVP and follow-up of HIV-infected infants beyond 2 weeks
Dec 2004 Informing IRBs of temporary change from NVP to second-line NFV for safety reasons.
June 2005 Changing study drug NVP to Lopinavir/ritonavir and SAE Reporting modifications
Nov 2005 Increasing reimbursement to equivalent of $4 in Malawi currency.
Mar 2006 Update NIH DAIDS Toxicity Table. Drop mothers’ dietary recall at 28 weeks to ease patient flow.
May 2006 Change in CD4 count eligibility: enroll only if >250 to meet new Malawi criteria for treatment. Drop mothers’ dietary recall at 32 and 48
weeks decrease time in clinic. Accept CD4 count from PMTCT program antenatally. Eliminate antenatal anthropometric measurements after
baseline to simplify procedures.
May 2007 LPV/r: Kaletra capsules changed to Aluvia tablets. Decrease breastfeeding questionnaires, breast physical exam forms, and all dietary recalls.
Stop storing cell pellets, PBMCs, PK samples. Decrease amount of breast milk stored. Mucosal substudy eliminated, reimbursement increased
to Malawi equivalent of $8 for intensive substudies. Addition of substudy – hepatitis study based on stored specimens.
July 2007 Amend consents to obtain permission to contact after end of study (at 48 weeks) for potential future studies.
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Table 5
NIH Division of AIDS previous and revised toxicity tables for definition of infant neutropenia and BAN
modification
DAIDS Toxicity Table
Cutpoints of infant neutropenia (cells/μL)
Day 1 Day 2–7 Day 8–56 Day > 57
Grade 1 5000–7000 1750–2500 1200–1800 750–1200
Grade 2 3000–5000 1250–1750 900–1200 400–750
Grade 3 1500–3000 750–1,250 500– 900 250–400
Grade 4 < 1,500 < 750 < 500 <250
Revised DAIDS Toxicity Table (December 2004)
Cutpoints for infant neutropenia (cells/μL)
Day 1 Day 2–7 Day 8–56 Day > 57
Grade 1 4000–5000 1250–1500 1000–1300 1000–1300
Grade 2 3000–4000 1000–1250 750–1000 750–1000
Grade 3 1500–3000 750–1,000 500– 750 500–750
Grade 4 < 1,500 < 750 < 500 <500
BAN Modification of Toxicity Table
Cutpoints for infant neutropenia (cells/μL)
Day 1 Day 2–7 Day 8–56 Day > 57
Grade 1 750–1200 750–1200 750–1200 750–1200
Grade 2 400–750 400–750 400–750 400–750
Grade 3 250–400 250–400 250–400 250–400
Grade 4 < 250 < 250 < 250 <250
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